<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04517656</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0601</org_study_id>
    <secondary_id>2020-A01901-38</secondary_id>
    <nct_id>NCT04517656</nct_id>
  </id_info>
  <brief_title>Biomarkers Impact Evaluation on the Post-transplant Immune Response After Allografting of Hematopoietic Stem Cells</brief_title>
  <acronym>MENTALO</acronym>
  <official_title>Biomarkers Impact Evaluation on the Post-transplant Immune Response After Allografting of Hematopoietic Stem Cells: MENTALO Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de la Loire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GIMAP EA3064 - Laboratoire d'Immunologie du CHU de Saint-Etienne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Cancérologie de la Loire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy or targeted therapy are usually used to treat hematological pathologies. Despite&#xD;
      of medical improvement, some of these pathologies present drug resistances, or high risk of&#xD;
      relapse. Hematopoietic stem cell (HSC) transplantation remain the gold standard of&#xD;
      consolidation, to maintain a durable response. In this situation, allograft with&#xD;
      hematopoietic stem cells donor aims at producing Graft-versus-Tumor effect, by producing a&#xD;
      new immune system, reproducing anti-tumoral immunity.&#xD;
&#xD;
      However, all hemopathies do not have the same sensibility. Nowadays, mechanisms underlying&#xD;
      this phenomenon remain poorly understood.&#xD;
&#xD;
      Indeed, few data precisely document the expression of immunological checkpoints and other&#xD;
      biomarkers in the context of allogeneic HSC transplantation, particularly their impact on&#xD;
      post-transplant outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chemotherapy or targeted therapy are usually used to treat hematological pathologies. Despite&#xD;
      of medical improvement, some of these pathologies present drug resistances, or high risk of&#xD;
      relapse. Hematopoietic stem cell (HSC) transplantation remain the gold standard of&#xD;
      consolidation, to maintain a durable response. In this situation, allograft with&#xD;
      hematopoietic stem cells donor aims at producing Graft-versus-Tumor effect, by producing a&#xD;
      new immune system, reproducing anti-tumoral immunity.&#xD;
&#xD;
      However, all hemopathies do not have the same sensibility. Nowadays, mechanisms underlying&#xD;
      this phenomenon remain poorly understood.&#xD;
&#xD;
      Indeed, few data precisely document the expression of immunological checkpoints and other&#xD;
      biomarkers in the context of allogeneic HSC transplantation, particularly their impact on&#xD;
      post-transplant outcome. Therefore, we want to systematically study the expression profile of&#xD;
      different biomarkers during allogeneic transplantation, in order to establish a correlation&#xD;
      between these expression patterns and post-transplant outcome. Ultimately, this research will&#xD;
      enable to (i) have tools to predict the post-transplant response and (ii) define whether a&#xD;
      targeted therapy could be beneficial or be contraindicated for adequate patient management.&#xD;
&#xD;
      Patients will be selected for the study once they meet all the inclusion criteria. The study&#xD;
      will be proposed to them during the pre-allogeneic consultation as part of their usual care.&#xD;
      This study does not modify the treatment or the usual management of patients according to the&#xD;
      current practice of pre- and post-transplant management. Clinically, it consists of building&#xD;
      up a relevant biological collection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Expression level of Programmed death-ligand (PD) plasmatic biomarkers</measure>
    <time_frame>12 months</time_frame>
    <description>Expression level of Programmed death-ligand (PD) plasmatic biomarkers will be quantified</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expression level of ST2 (suppression of tumourigenicity 2) plasmatic biomarkers</measure>
    <time_frame>12 months</time_frame>
    <description>Expression level of ST2 (suppression of tumourigenicity 2) plasmatic biomarkers will be quantified</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expression level of Reg3 (regenerating islet-derived 3-alpha) plasmatic biomarkers</measure>
    <time_frame>12 months</time_frame>
    <description>Expression level of Reg3 (regenerating islet-derived 3-alpha) plasmatic biomarkers will be quantified</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expression level of Elafin plasmatic biomarkers</measure>
    <time_frame>12 months</time_frame>
    <description>Expression level of Elafin plasmatic biomarkers will be quantified</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Malignant Hemopathy</condition>
  <arm_group>
    <arm_group_label>patients with hematologic malignancy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patient, over 18 years old, suffering from a malignant hemopathy (without exception) for whom an allogeneic hematopoietic stem cell transplant from a related or unrelated donor is indicated</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>A peripheral blood sample will be taken and will include 2 EDTA tubes of 5 mL, for a total volume of 10 mL:&#xD;
Samples before the allograft,&#xD;
Samples at different times post-allograft: 15 days, 30 days, 60 days, 90 days, 180 days, 360 days,&#xD;
Samples in the event of the occurrence of concomitant events during the 12-month follow-up period: occurrence of acute Graft Versus Host Disease, chronic Graft Versus Host Disease, or relapse of the disease before the initiation of a new treatment.</description>
    <arm_group_label>patients with hematologic malignancy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient, over 18 years of age, suffering from a malignant hemopathy (without&#xD;
             exception),&#xD;
&#xD;
          -  Patient for whom an allogeneic hematopoietic stem cell transplant from a related or&#xD;
             unrelated donor is indicated,&#xD;
&#xD;
          -  Signed informed consent,&#xD;
&#xD;
          -  Patient covered by a social security scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allogeneic hematopoietic stem cell transplantation from cord blood or haplo-identical&#xD;
             transplant,&#xD;
&#xD;
          -  Allogeneic transplant with post-transplant cyclophosphamide treatment,&#xD;
&#xD;
          -  Allograft with sequential conditioning.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérôme Cornillon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie Lucien Neuwirth</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jérôme Cornillon, MD</last_name>
    <phone>477917089</phone>
    <phone_ext>+33</phone_ext>
    <email>elisabeth.daguenet@icloire.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabeth Daguenet, PhD</last_name>
    <phone>477917089</phone>
    <phone_ext>+33</phone_ext>
    <email>elisabeth.daguenet@icloire.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jérôme Cornillon, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Elisabeth Daguenet, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jérôme Cornillon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Guyotat, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Lejeune, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle Tavernier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allograft</keyword>
  <keyword>Hematopoietic stem cells</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Immune response</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

